TrialSignal
Clinical trial intelligence report
Long-Term Outcomes of Participants Treated With Teplizumab in Routine Clinical Care
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT07360080
Status
RECRUITING
Phase
Observational
Sponsor
Sanofi
Executive brief
Investment-Ready Snapshot
Sanofi is conducting a prospective cohort study to evaluate the long-term outcomes of teplizumab treatment in patients with Stage 2 Type 1 Diabetes. The study aims to assess the drug's effectiveness in delaying the onset of Stage 3 T1D and its impact on patients' quality of life through various patient-reported outcomes.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07360080
Indication
Type 1 Diabetes
Modality
monoclonal antibody
Target
Type 1 Diabetes (Stage 2)
Intervention
Teplizumab
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.